Nov 19 (Reuters) – The US Food and Drug Administration said on Thursday it had established a new internal safety body within its biologics center, formalizing independent oversight of approved products such as vaccines, gene therapies and blood products once they reach the market.
The CBER Safety Council will report directly to the director of the FDA’s Center for Biologics Evaluation and Research, structurally separating post-market safety reviews from the offices responsible for approving those products, the agency said.
Here are some details:
• The council supersedes CBER’s existing Safety Working Group, bringing together senior scientific and regulatory officials to review safety signals, conduct benefit-risk assessments and recommend regulatory actions as warranted
• The new structure formalizes an independent post-market review process at a time when regulators face mounting pressure to closely monitor newer biologic products, including gene and cell therapies, after approval, when they are used across far broader patient populations
• Its mandate will cover emerging safety concerns, potential labeling changes, risk-management measures and safety-related post-market studies, as well as advising on potential market withdrawals
• The FDA said the council is intended to improve accountability and transparency as biologic products grow increasingly complex, particularly in cell and gene therapy, a sector that has seen rapid regulatory expansion in recent years
• The council will coordinate with external bodies including the US Centers for Disease Control and Prevention and the National Institutes of Health, drawing on surveillance systems such as the Vaccine Adverse Event Reporting System (VAERS) and the FDA Sentinel program
• The council takes effect on November 19; the agency said additional details on its structure and membership will be released later
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Tasim Zahid)

